Why "Wait and See" Isn't an Option

Mon, Mar 11, 2019 | By Lindsay Belcher, Business Development Director - Northeast, Cryoport

It’s happening…are you ready? As we are coming to the end of Q1 2019, the FDA recently finalized two guidance documents regarding Regenerative Medicine (as of Feb 15, 2019). There is no doubt FDA...

Shipping Validations are Common Shipping New Pharmaceutical Products - But Who ‘Validates’ the Carriers? Cryoport Can!

Thu, Mar 07, 2019 | By Kirk Randall, Senior Director, Business Development, Cryoport

In choosing a logistics provider and important factor is to find someone who is carrier agnostic. So what does that mean? It means the solution provider is able to use, and track the performance of,...

Ensure Chain of Compliance® in Your Supply Chain

Mon, Feb 25, 2019 | By Cryoport Team

Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. But the fragility of regenerative medicine therapies – and the need...

How to Prevent Damage to Biomaterials During Shipment

Wed, Feb 20, 2019 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport

We’re often asked by our clients what packaging and containment materials should be used to help prevent damage to their shipment contents.In reviewing shipper “packouts” with clients for upcoming...

FDA’s Recent Outlook and New Policies for Cell and Gene Therapies

Mon, Feb 11, 2019 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport

On January 15th FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D, Director of the Center for Biologics Evaluation and Research released a public statement which outlined new policies...

Cancer MoonShot 2020 Initiative Spurs Immunotherapy Research and Integrated Logistics Need

Thu, Jan 19, 2017 | By Mark W. Sawicki, Ph.D., Chief Commercial Officer, Cryoport

Providing $6.3 billion in funding for medical innovation to expedite the discovery, development and delivery of new treatments and cures, the 21st Century Cures Act (Cures) received overwhelming...

Helping Hospitals Unmask Cancer

Mon, Feb 29, 2016 | By Robert Hariri, M.D., Ph.D., Board of Directors, Cryoport

During the 2016 Super Bowl, New York-Presbyterian Hospital aired a 60-second advertisement, titled “Unmasking a Killer,” highlighting the hospital’s advanced cancer research and treatment. The ad...

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC